AQR Capital Management
INMB icon

AQR Capital Management’s INmune Bio INMB Stock Holding History

AQR Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Buy
270,317
+249,798
+1,217% +$356K ﹤0.01% 3396
2025
Q4 		$32K Buy
20,519
+213
+1% +$380 ﹤0.01% 3532
2025
Q3 		$42K Buy
+20,306
New +$46.5K ﹤0.01% 3428

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

AQR Capital Management's INMB Position: Q1 2026 in Review

AQR Capital Management increased its INmune Bio (INMB) stake by 1,217% in Q1 2026, buying an estimated $356K and bringing the position to 270,317 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

AQR Capital Management first reported a position in INMB in Q3 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • AQR Capital Management held 270,317 shares of INmune Bio worth $305K as of Q1 2026.
  • AQR Capital Management bought 249,798 INmune Bio shares in Q1 2026, an estimated $356K.
  • INmune Bio made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3396 holding.
  • AQR Capital Management first reported a position in INmune Bio in Q3 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.